In the relapsed and refractory setting, salvage chemotherapy and auto stem-cell transplantation outcomes are extremely poor for patients with MYC+ disease (CORAL study: Collaborate Trial in Relapsed Aggressive Lymphoma), where 75% patients had FISH evidence of DHL. The gene discussed is MYC; the disease is lymphoma.